Sonoma Pharmaceuticals, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Sonoma Pharmaceuticals, Inc. (SNOA) on April 8, 2026. The report discloses the entry into a material definitive agreement regarding the company's Microcyn technology-based products.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on a contractual agreement rather than periodic financial performance data.
Material Changes and Agreements
- Agreement Type: Manufacturing and Supply Agreement.
- Counterparty: Kenvue Brands LLC.
- Scope: Sale of Microcyn technology-based products in the United States.
- Effective Period: October 24, 2025, through March 2027.
- Extension Terms: Subject to up to two additional one-year terms upon mutual written agreement.
Guidance, Outlook, and Risks
The filing contains standard forward-looking statements regarding intentions, beliefs, and expectations. Management notes that actual outcomes may differ materially due to risks and uncertainties discussed in the company's Annual Report on Form 10-K. No specific financial guidance or outlook figures are provided in this document.
Investor Verification Checklist
- Review the full text of the Manufacturing and Supply Agreement (Exhibit 10.1) for specific financial terms, royalties, or volume commitments, as certain portions were omitted for confidentiality.
- Verify the strategic impact of the partnership with Kenvue Brands LLC on future revenue streams.
- Check the company's most recent Form 10-K for detailed risk factors and historical financial performance.